{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:21Z","timestamp":1789011081330,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11239-019-01993-9","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T20:01:38Z","timestamp":1573761698000},"page":"413-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-2776","authenticated-orcid":false,"given":"Armando","family":"Tripodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Chantarangkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marigrazia","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Scalambrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"1993_CR1","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","volume":"127","author":"N Uchida","year":"2016","unstructured":"Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S et al (2016) A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 127:1633\u20131641","journal-title":"Blood"},{"key":"1993_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 377:809\u2013818","journal-title":"N Engl J Med"},{"key":"1993_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME et al (2018) Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 379:811\u2013822","journal-title":"N Engl J Med"},{"key":"1993_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1055\/s-0039-1688687","volume":"119","author":"JI Adamkewicz","year":"2019","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I (2019) Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 119:1084\u20131093","journal-title":"Thromb Haemost"},{"key":"1993_CR5","first-page":"547","volume":"88","author":"V Chantarangkul","year":"2003","unstructured":"Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A (2003) Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 88:547\u2013554","journal-title":"Haematologica"},{"key":"1993_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000071636","volume":"33","author":"HC Hemker","year":"2003","unstructured":"Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4\u201315","journal-title":"Pathophysiol Haemost Thromb"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/01.mbc.0000169217.15926.d0","volume":"16","author":"JL Francis","year":"2005","unstructured":"Francis JL, Hursting MJ (2005) Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 16:251\u2013257","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1993_CR8","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1016\/S0021-9258(17)37260-5","volume":"269","author":"PJ Lenting","year":"1994","unstructured":"Lenting PJ, Donath MJ, van Mourik JA, Mertens K (1994) Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269:7150\u20137155","journal-title":"J Biol Chem"},{"key":"1993_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1021\/bi201731p","volume":"51","author":"M Takeyama","year":"2012","unstructured":"Takeyama M, Wakabayashi H, Fay PJ (2012) Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry 51:820\u2013828","journal-title":"Biochemistry"},{"key":"1993_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A et al (2017) Factor VIII-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 117:1348\u20131357","journal-title":"Thromb Haemost"},{"key":"1993_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jth.14334","volume":"17","author":"H Minami","year":"2019","unstructured":"Minami H, Nogami K, Yada K, Ogiwara K, Furukawa S, Soeda T et al (2019) Emicizumab, the bispecific antibody to factors IX\/IXa and X\/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. J Thromb Haemost 17:126\u2013137","journal-title":"J Thromb Haemost"},{"key":"1993_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/jth.14556","volume":"17","author":"M Makris","year":"2019","unstructured":"Makris M, Iorio A, Lenting PJ (2019) Emicizumab and thrombosis: the story so far. J Thromb Haemost 17:1269\u20131272","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-01993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T07:17:35Z","timestamp":1612336655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-01993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01993-9","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"14 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}